Put Calls Anyone?

Image via Wikipedia Arena Pharmaceuticals is in a tough spot as the FDA rejects their weight loss drug lorcaserin, apparently one of the safer of the 3 up for approval.

Here is the link to investors. 

This decision was expected and predicted in my past articles on the Obesity Drug Market.  We all saw it coming.  I'm sorry if you didn't.  But expect loses for Orexigen, and Vivus with their upcoming FDA decisions.   I can only see gains made with shorting the stocks.  Those that had are sitting pretty right now.  It's a gamble but sometimes these gambles pay off.  I expect more loses to mount for these companies in the near future.  Arena Pharmaceuticals, Vivus Inc., and Orexigen Therapeutics.

What they chose to do next is anyones guess.  The technology could be sold off for further research.  And the company enters bankruptcy court.  Nonetheless just passing on the news.  I'm not always right but some are easier to pick than others.  Last weeks news of Amylin, Alkermes, and Eli Lilly and Company for their diabetes medicine was a heartbreaker for those who thought it would go the other way.  But there are always more to look at.  Keep looking forward and use it as a lesson.

Arena Pharmaceuticals Enters FDA Purgatory

Welcome to FDA purgatory, Arena Pharmaceuticals. It could be a long wait.

The Essential Biotech Sector Fall Preview

Try WikInvest Here:--;https://www.wikinvest.com/

Stock quotes in this article: DNDN, HGSI, GENZ, ARNA, AMLN, IDIX, PCYC

The Essential Biotech Sector Fall Preview

BOSTON (TheStreet) -- Labor Day is over and Hurricane Earl is out to sea, which means Wall Street is returning to work in earnest for the last three months of the year. To put everyone in the right mindset, I've compiled a "Back to School" guide covering the essential information biotech investors need to profit from what should be a very busy fall season.

FDA Advisory Panels Recommends Fewer Drugs This Year

Image via Wikipedia It has been a rough year for Drug Candidates this year. Time after time FDA panels are rejecting more qualified drug approvals. So what really is going on here. Are drug up for FDA approval less safe, less effective, or are the panels more cautious on approvals. These panels have had a devastating effect on the company's stock after these No recommendations. Let's take a closer look into what's really going on.

FDA Advisory Panels: A Coin Flip

Market Thoughts for Wednesday August 11th

The market took a hammering today but some stocks actually performed or are now great buys. The DOW Industrial average DIJA is closing sharply lower today at 10379. That's a 265 drop from yesterdays close of 10644 and a 2.49% decline as Global Fear strikes domestic and foreign markets.

Today's top performers in BioPharma for August 11th.

Biotech

Monday's BioPharma List for August 9th

Top Pharmaceuticals for Monday August 9th

1. K-V Pharmaceuticals This one is slightly unpredictable (NYSE:KV.A) at 1.46 up +0.17 a 13.17% gain after having a 20.6% increase last week.

2. Roche Holdings RHHBF; F denotes a foreign stock trading on Nasdaq this quote is from last week as this stock trades based on a foreign market. Last week up 10.50 at 142.00 a 10.50% gain. The stock has been down as of late but I predict that things could change in the near future for the better.

Their US Based stock RHHBY was flat today. (RHHBY)

Top BioPharma Pipeline Plays August 2010

Image via CrunchBase Stocks currently on my Watchlist for top BioPharma plays in the near future.

1. Valeant Pharmaceuticals (NYSE:VRX)

Biotechnology Research Report on Valeant's Potiga

On August 11, 2010, we expect the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee to review the marketing application of Valeant Pharmaceuticals International’s (VRX) Potiga (formerly known as Retigabine), designed for the treatment of partial-onset seizures in epilepsy patients who have become refractory (failing to show response to prior therapy) to anti-epilepsy drugs (AEDs).

Three Hot BioPharma Investment Plays: ARNA, JAZZ, and PRAN

 I have a few investment plays in the BioPharma field that I would like to share with everyone. These plays include Arena Pharmacueticals, Jazz Pharmaceuticals, and Prana Biotechnology. The first play is Arena Pharmaceuticals NASDAQ:ARNA. JP Morgan recently downgraded the stock Monday August 2 to Neutral, however Jim Cramer recommended the stock as a buy last Friday on his show MadMoney. Today's afterhours earnings estimate for Q2 was a better than expected loss and I see the stock rising heavily in the next month with the highly anticipated FDA panel review September 16th. ---I have since changed my outlook on all these stocks and actually recommend shorting them lately.